tiprankstipranks
Trending News
More News >
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609)
:6609
Hong Kong Market
Advertisement

Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis

Compare
1 Followers

Top Page

HK:6609

Shanghai Heartcare Medical Technology Corp. Ltd. Class H

(6609)

Rating:61Neutral
Price Target:
HK$47.00
▼(-6.75%Downside)
The stock's score is driven primarily by its strong technical momentum, despite its overbought condition. Financial performance shows potential with strong revenue growth and a stable balance sheet, but is offset by profitability and cash flow challenges. The valuation remains weak due to a negative P/E ratio and lack of a dividend yield.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model

Company DescriptionShanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyShanghai Heartcare Medical Technology Corp. Ltd. generates revenue through the sale of its cardiovascular medical devices and solutions to hospitals, clinics, and healthcare providers. The company invests in research and development to continuously innovate and enhance its product offerings, ensuring they meet the evolving needs of the medical community. Additionally, the company may engage in strategic partnerships and collaborations with other healthcare and medical technology firms to expand its market reach and distribution channels. Factors such as advancements in medical technology, increasing demand for minimally invasive procedures, and the growing prevalence of cardiovascular diseases contribute to the company's earnings potential.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview

Summary
Strong revenue growth and a stable balance sheet with low leverage and high liquidity are positives. However, persistent net losses and negative cash flow highlight the need for improved profitability and cash management strategies.
Income Statement
65
Positive
The company has shown a positive revenue growth trajectory with a significant increase in total revenue over the years. Gross profit margin is healthy, but the net profit margin remains negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins are also negative, showing operational inefficiencies.
Balance Sheet
70
Positive
The balance sheet is strong with a high equity ratio and low debt-to-equity ratio, indicating financial stability and low leverage. However, the company has been experiencing net losses, affecting its return on equity negatively. High cash reserves provide a strong liquidity position.
Cash Flow
50
Neutral
The company has faced challenges in generating positive operating cash flow, with negative free cash flow indicating difficulties in covering capital expenditures. The absence of positive cash flow metrics suggests a need for better cash management and operational efficiency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue277.90M232.34M183.03M90.09M14.56M
Gross Profit181.72M163.76M124.33M54.95M7.09M
EBITDA21.87M-68.50M-167.31M-183.34M-206.19M
Net Income-13.62M-94.01M-200.38M-195.82M-216.08M
Balance Sheet
Total Assets1.21B1.20B1.31B1.50B773.63M
Cash, Cash Equivalents and Short-Term Investments713.72M721.14M870.12M1.22B632.42M
Total Debt35.75M36.38M50.69M41.94M24.69M
Total Liabilities144.00M125.60M147.08M132.10M82.60M
Stockholders Equity1.06B1.08B1.17B1.37B681.37M
Cash Flow
Free Cash Flow-8.39M-137.72M-304.01M-260.33M-90.42M
Operating Cash Flow-3.23M-88.41M-266.77M-205.85M-74.81M
Investing Cash Flow10.80M-125.45M44.84M-161.10M-4.53M
Financing Cash Flow-12.38M-21.48M-24.75M821.25M686.22M

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price50.40
Price Trends
50DMA
35.85
Positive
100DMA
32.35
Positive
200DMA
27.61
Positive
Market Momentum
MACD
3.99
Negative
RSI
76.02
Negative
STOCH
89.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 50.4 is above the 20-day moving average (MA) of 42.70, above the 50-day MA of 35.85, and above the 200-day MA of 27.61, indicating a bullish trend. The MACD of 3.99 indicates Negative momentum. The RSI at 76.02 is Negative, neither overbought nor oversold. The STOCH value of 89.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
HK$1.96B-1.28%17.45%85.71%
58
Neutral
£4.95B6.56-62.36%103.85%34.03%6.31%
€593.03M-10.43%
69
Neutral
HK$8.42B35.786.49%0.87%-18.05%
52
Neutral
HK$3.06B-2.19%5.32%89.43%
HK$2.76B-3.13%
46
Neutral
HK$1.27B-27.82%-6.12%0.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
50.05
34.97
231.90%
DE:4WO
Peijia Medical Ltd.
0.88
0.42
91.30%
HK:1302
LifeTech Scientific Corporation
1.95
0.56
40.29%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.32
0.59
80.82%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.35
2.55
67.11%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.82
-2.80
-49.82%

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events

Shanghai HeartCare Announces H Share Register Closure for 2025 EGM
Jul 15, 2025

Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from July 30, 2025, to August 29, 2025, to determine shareholders eligible to attend and vote at the 2025 second extraordinary general meeting scheduled for August 29, 2025. This move is significant for shareholders as it dictates the timeline for share transfers and eligibility to participate in the company’s decision-making process during the EGM.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Successfully Concludes 2024 AGM and EGM
May 26, 2025

Shanghai HeartCare Medical Technology Corp. Ltd. successfully held its 2024 Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) on May 26, 2025, where all proposed resolutions were passed by poll. The meetings were conducted in compliance with the Company Law of the PRC and the Articles of Association, with significant shareholder participation, indicating robust governance and stakeholder engagement.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai Heartcare Announces EGM to Discuss 2025 H Share Incentive Scheme
May 7, 2025

Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.

Shanghai HeartCare Proposes 2025 H Share Incentive Scheme
May 7, 2025

Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025